Type of Cancer
Lymphoma
Phase
Division (Location)
Study ID
NCT#
Brief Description
PHASE 1/2 STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF SINGLE AGENT CC-122 AND THE COMBINATIONS OF CC-122 AND RITUXIMAB AND CC-122 AND IBRUTINIB IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.